

FORM PTO-1449 (modified)  
To: U.S. Department of Comm.  
Patent and Trademark Office

Attorney Docket No.

Client Ref.

056291-5207

Applicant: Alan BARGE

Appln. No.: Unassigned

Filing Date: May 12, 2005

Examiner: Unassigned

Group Art Unit: Unassigned

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: May 12, 2005

Page 1 of 1

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					

## FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	DR	02057271 A1	07/2002	WO	Raymond J.A. Budde et al.				
	ER								
	FR								
	GR								
	HR								

## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	IR	M. Michael et al., "Clinical Experience With Gemcitabine in Pancreatic Carcinoma". Oncology, S. Karger AG, Basel CH, Vol. 11, No. 11, November 1997, pp. 1615-1622.			
	JR	Manfred P. Lutz et al., "Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma". Biochemical and Biophysical Research Communications, Vol. 243, No. 2, February 13, 1998, pp. 503-508.			
	KR	Hiromichi ITO et al., "Inhibition of Tyrosine Kinase Src Suppresses Pancreatic Cancer Invasiveness". Surgery (St. Louis), Vol. 134, No. 2, August 2003, pp. 221-226.			

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.